Cagrilintide

Mechanism

Cagrilintide is a synthetic long-acting amylin analog developed by Novo Nordisk. Amylin is a hormone co-secreted with insulin from pancreatic beta cells; it slows gastric emptying and promotes satiety through a different receptor system than GLP-1 (specifically, the amylin and calcitonin receptors).

The compound is most-studied as part of CagriSema — a fixed-dose combination with semaglutide currently in Phase 3 obesity trials. The pairing combines amylin-receptor activation (cagrilintide) with GLP-1 receptor activation (semaglutide), targeting two complementary satiety pathways. Published Phase 2 data has shown weight-loss outcomes that exceed semaglutide alone, though direct comparison with tirzepatide is the open question.

Cagrilintide alone is studied less widely in research-protocol literature than the combination form. Most vendor catalog listings position it as a stack-with-semaglutide compound.

Research dosing

The Phase 2 dose-escalation literature spans 0.16 mg → 4.5 mg weekly subcutaneous, with the higher doses producing the strongest weight-loss signal. Research-protocol references typically cite:

• 2.4 mg weekly as a mid-range maintenance dose
• 4.5 mg weekly as the upper end of published Phase 2 studies
• Cycled or escalated dosing — direct jumps to the higher dose produce more GI side effects

Half-life of approximately seven days supports weekly administration, matching the semaglutide schedule when the two are stacked.

Side-effect profile

Reported side effects from Phase 2 trials cluster in the GLP-1-class-typical pattern:

• Nausea, vomiting, diarrhea — most common, dose-dependent, concentrated in titration
• Mild injection-site reactions at higher doses
• No distinct cardiovascular signal in published Phase 2 data, in contrast to retatrutide's heart-rate observation

What we cover

Public Janoshik testing data on cagrilintide is currently sparse — only one publicly-submitted test in our local mirror as of May 2026. As more vendors add the compound to their catalogs, the data layer below will populate. Until then, vendor audits for cagrilintide rely on identity confirmation alone; cross-vendor purity comparison isn't yet meaningful at this n.